6月5日 - ** 券商瑞银将生物技术公司Blueprint Medicines Corp BPMC.O的预测价格从88美元上调至129美元，与赛诺菲对该公司的收购价格 一致
** 维持 "中性 "评级
** 法国制药商赛诺菲SASY.PA周一表示， (link)，同意以高达95亿美元的价格收购BPMC，以提升其在罕见免疫疾病领域的地位。
** 瑞银认为两家公司的产品组合重叠有限或没有重叠
** 赛诺菲获得Ayvakit，用于治疗一种名为 "晚期和隐匿性系统性肥大细胞增多症 "的罕见免疫疾病，2024年收入将达4.789亿美元--瑞银（UBS
** 包括本交易日走势在内，该股今年累计上涨 46.9
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.